Hepatic artery chemotherapy in the management of colorectal metastases

Stacy L. Stratmann, MD

From the Department of Surgery, Baylor University Medical Center, Dallas, Texas.

Corresponding author: Stacy L. Stratmann, MD, 3600 Gaston Avenue, Suite 958, Dallas, Texas 75246.

Hepatic artery infusion (HAI) chemotherapy should be considered for all patients with metastatic colorectal cancer confined to the liver. HAI-floxuridine therapy has improved tumor response rates for patients with resectable and unresectable disease. Also, HAI therapy appears to improve 2-year survival rates for patients who have undergone hepatic resection. A trend toward survival advantage for patients with unresectable disease has been identified, although it remains to be statistically proven. Furthermore, HAI may improve quality of life for patients, while cost is congruent with treatment for other severe medical illnesses. (BUMC Proceedings 2002;15:376-379)